The Drugs for Neglected Diseases initiative (DNDi) has gained access to the Pfizer library of novel chemical entities. DNDi will screen the compounds for their potential to be developed into new treatments for human African trypanosomiasis (HAT), visceral leishmaniasis (VL), and Chagas disease.
Under the agreement, scientists in institutes affiliated with DNDi will test at least 150,000 compounds in the Pfizer library against Trypanosoma brucei, Leishmania donovani, and Trypanosoma cruzi, the parasites that cause HAT, VL, and Chagas disease, respectively. Researchers will seek compounds that show initial activity against the various parasites.
